Bevacizumab-maly
Bevacizumab-Maly is an anti-angiogenic medication belonging to the monoclonal antibody class, specifically designed to inhibit vascular endothelial growth factor (VEGF). This drug is used in the treatment of various cancers by preventing the formation of new blood vessels that tumors need to grow and spread. As a bevacizumab-based therapy, it is typically administered via intravenous infusion under specialist supervision.
Bevacizumab-Maly is an anti-cancer monoclonal antibody that inhibits tumor blood vessel formation by targeting VEGF.
Key facts at a glance
- RxNorm
- 2599041
- Generic
- Bevacizumab-Maly
- Class
- pin-variant
- Brands
- Alymsys
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Used to treat various cancers including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, glioblastoma, ovarian cancer, and cervical cancer. Treatment is determined by oncologists based on cancer type and stage.
This medication is a monoclonal antibody that specifically binds to vascular endothelial growth factor (VEGF), preventing it from interacting with its receptors on endothelial cells. By blocking VEGF signaling, it inhibits angiogenesis (the formation of new blood vessels), thereby starving tumors of their blood supply and inhibiting tumor growth.
Administered by intravenous infusion. Common side effects include hypertension, proteinuria, fatigue, and wound healing complications. Serious risks include gastrointestinal perforation, hemorrhage, and arterial thromboembolism. Requires monitoring by oncology specialists. Pregnancy category X - contraindicated in pregnancy. May interact with other anti-angiogenic agents or immunosuppressants.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy